Formulation and Evaluation of Emulgel Containing Sucralfate and Dimethicone; A Novel Transdermal Pharmaceutical Dosage Form

Considering the lack of oxygen, prolonged pressure, and infection are common features of most chronic wounds, especially in pressure ulcers, finding a way to heal the wounds at the early stages is essential. Various pharmaceutical dosage forms are used to act against the infection and prevent the development of this painful condition. The present study aimed to prepare and evaluate topical emulgel formulation for use in the treatment of patients with grade I and II bedsore. The formulation was prepared through the oil in water (o/w) emulsion of organic and aqueous parts to prepare a depot for the transfer of the hydrophobic drug. Emulgel contains sucralfate (Suc), as the epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) could increase the wound healing rate in these patients. The results showed that the emulgel was stable, homogenous non-discolored, and had a constant pH. In terms of microbial content, it was within the acceptable range of pharmacopeia, and the preservatives had a suitable performance. The product had good spreadability. Rheological studies demonstrated that the prepared formulation had thixotropic properties, which is one of the most critical indicators in the design of semi-solid pharmaceutical forms. Topical emulgel containing Suc can be used as an effective pharmaceutical dosage form to treat grade I and II bedsore due to its innovative pharmacological form and the benefits of this drug form along with the moisturizing, softening, and protecting properties of dimethicone and unique properties of Suc.